Showing results (2521-2530 of 3,679) with videos related to

Sort By:
Pageof 368
Human Molecular Genetics|February 1, 1994
Olfactory receptor gene cluster on human chromosome 17: possible duplication of an ancestral receptor repertoireN Ben-Arie, D Lancet, C Taylor, et al.
Medical and Pediatric Oncology|August 5, 2000
P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell linesA C Taylor, L Shu, M K Danks, et al.
Drug and Alcohol Dependence|November 16, 2018
The relationship between smoking cessation and binge drinking, depression, and anxiety symptoms among smokers with serious mental illnessPatrick J Hammett, Harry A Lando, Brent C Taylor, et al.
Brain Research Bulletin|October 10, 2006
Relative expression of D3 dopamine receptor and alternative splice variant D3nf mRNA in high and low responders to noveltyLaurel M Pritchard, Aaron D Logue, Benjamin C Taylor, et al.
British Journal of Cancer|August 5, 2004
Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohortJ Peto, C Gilham, J Deacon, et al.
Osteoarthritis and Cartilage|January 26, 2012
Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254)V B Kraus, J Birmingham, T V Stabler, et al.
The ISME Journal|September 26, 2015
Genomic and metagenomic surveys of hydrogenase distribution indicate H2 is a widely utilised energy source for microbial growth and survivalChris Greening, Ambarish Biswas, Carlo R Carere, et al.
Current Pharmaceutical Design|November 25, 2020
Bioluminescent:Fluorescent Trypanosoma cruzi Reporter Strains as Tools for Exploring Chagas Disease Pathogenesis and Drug ActivityMartin C Taylor, Alexander I Ward, Francisco Olmo, et al.
Rheumatology and Therapy|January 9, 2020
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b TrialsJacqueline M Tarrant, René Galien, Wanying Li, et al.
The Journal of Rheumatology|August 17, 2017
Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid ArthritisEdward C Keystone, Mark C Genovese, Douglas E Schlichting, et al.
Pageof 368